|Bid||3.3600 x 2900|
|Ask||3.3700 x 900|
|Day's Range||3.2500 - 3.7000|
|52 Week Range||1.9800 - 17.2200|
|Beta (5Y Monthly)||2.31|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for STIM
Cannell Capital is now an active investor in biotech Neuronetics. Jana Partners lifted its investment in telemetry-analytics platform provider New Relic.
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
Good morning, and thank you for joining us for Neuronetics' First Quarter 2022 conference call. Joining me on today's call are Neuronetics' president and chief executive officer, Keith Sullivan; and the SVP chief financial officer and treasurer, Steve Furlong. Before we begin, I would like to caution listeners that certain information discussed by management during this conference call will include forward-looking statements covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements related to our business, strategy, financial and revenue guidance, the impact of COVID-19 and other operational issues and metrics.